Neutekbio introduces its newest product: iLite antibeta for the detection and measurement of neutralising antibodies (NAbs) to Interferon beta (IFNB)
iLite antibeta is based on a conventional gene reporter format, but utilises Neutekbio's patented division-arrested cell technology, the iLite Reporter Cells, which quantitatively respond to IFNB.
The assay is designed to replace or complement the current time consuming and labour-intensive methods such as cytopathic effect assay (CPE) and MxA.
Assay results are available within approximately 19 hours.
In studies using clinical samples, iLite antibeta demonstrates increased sensitivity in the detection of low-titre positive samples when compared to traditional methods.
The assay can be used for either initial screening of samples, or for a specific NAb titre of positive samples.
No costly and continuous cell culture requirements.
The iLite IFNB sensitive cells are simply thawed when needed, and the assay is ready to go.
There is no need for infectious virus standard preparations which are required by the current time consuming and less reliable tests.
No more unacceptable intra-assay variability seen with more subjective assays.
Neutekbio development and manufacturing facilities operate to ISO13485 quality management systems.
The final product is subjected to rigorous quality release testing, ensuring reproducibility and reliability.
Due to its simple 96 well format and ease of use, the iLite assay is easily transferable to a CRO for clinical investigations, needing a lower level of technical expertise than other techniques available.
